Medimix Hematology
  • Home
  • Live from the congress
    • 2025
      • EHA 2025
      • ICML 2025
      • EBMT 2025
    • 2024
      • ASH 2024 (San Diego)
      • EHA 2024 (Madrid)
      • ASCO 2024 (Chicago)
  • Contact
  • Other specialties
    • Dermatology
    • Oncology
  • SIGN UP
  • SIGN IN
    • Login
EHA 2024

Brentuximab vedotin + pembrolizumab in R/R cHL

July 17, 2024

Presented by Dr Hanne Massa (Jules Bordet Institute, Brussels, Belgium)

The current standard treatment for R/R cHL involves salvage chemotherapy followed by ASCT. However, the optimal salvage therapy regimen remains undefined. Recent evidence suggests that the combination of brentuximab vedotin (BV) with PD-1 inhibitors may yield promising outcomes in this context.

Dr Hanne Massa, a haematologist in training at the Jules Bordet Institute in Brussels, presented a single centre retrospective analysis evaluating the efficacy and safety of BV and pembrolizumab as salvage therapy prior to ASCT, followed by BV maintenance, in patients with R/R cHL.

References:

Massa H, EHA2024 #P1105

With the educational support of:

Back to congress overview

Tags:

poster

Share Article

Medimix Hematology

Website created by MediMix © 2025 - Privacy Policy

  • Home
  • Live from the congress
    • 2025
      • EHA 2025
      • ICML 2025
      • EBMT 2025
    • 2024
      • ASH 2024 (San Diego)
      • EHA 2024 (Madrid)
      • ASCO 2024 (Chicago)
  • Contact
  • Other specialties
    • Dermatology
    • Oncology
  • SIGN UP
  • SIGN IN
    • Login
    • Logout
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok